Overview
Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 27, 2025 | Adaptam Therapeutics: €3 Million Raised To Develop Immunotherapies Targeting Tumor-Associated Myeloid Cells | Adaptam Therapeutics, a biotechnology company pioneering cancer immunotherapies designed to overcome immunosuppression within the tumor microenvironment, announced the successful completion of a €3 million (about $3.5 million) pre-seed fina... |
| Oct 27, 2025 | Adaptam Therapeutics raises €3M to advance cancer immunotherapies | San Sebastián and Barcelona-based biotech Adaptam Therapeutics has raised €3 million in a pre-seed round led by Criteria Bio Ventures to develop first-in-class antibody therapies targeting immunosuppressive myeloid cells in solid tumours. T... |
| Sep 13, 2016 | CIC bioGUNE, CRB Inverbío, Kereon Partners y BA crean la compañía Atlas Molecular Pharma | 13/09/2016 CIC BIOGUNE, CRBINVERBÍO, KEREON PARTNERS Y BUSINESS ANGELS CREAN LA COMPAÑÍA ATLAS MOLECULAR PHARMA. El centro de investigación CIC bioGUNE, las entidades de capital riesgo (venture capital) CRB Inverbío y Kereon Partners, e i... |
Reviews 0
FAQ about CIC bioGUNE
When was CIC bioGUNE founded?
CIC bioGUNE was founded in 2003.
What has the press written about CIC bioGUNE?
Parsers VC has collected 4 articles mentioning CIC bioGUNE, among them “Adaptam Therapeutics: €3 Million Raised To Develop Immunotherapies Targeting Tumor-Associated Myeloid Cells” (Oct 27, 2025) and “Adaptam Therapeutics raises €3M to advance cancer immunotherapies” (Oct 27, 2025).
Is CIC bioGUNE still active?
Yes, CIC bioGUNE is active; its latest activity on Parsers VC dates from Oct 27, 2025.